Ambu A/S crushes Q1 2026 earnings with endoscopy boom: because 'synergy' in single-use devices beats another pivot to AI

Ambu A/S, a Danish medical device company, released its Q1 2026 earnings report, highlighting its financial performance for the quarter. The company's results indicate a steady growth in revenue, driven by increased demand for its single-use endoscopes. Ambu A/S reported a revenue of DKK 943 million, a 10% increase compared to the same quarter last year. The company's CEO, Britt Meelby Jensen, attributed the growth to the expanding use of single-use endoscopes in hospitals and clinics, citing the benefits of reduced infection risk and increased patient safety. The earnings call presentation also highlighted Ambu's strategic investments in research and development, aimed at expanding its product portfolio and strengthening its position in the global medical device market. With its Q1 results, Ambu A/S reaffirms its commitment to delivering high-quality medical solutions, aligning with the industry's shift towards single-use devices and addressing the growing need for infection control measures.